Net margin is calculated as Net Income divided by its Revenue. Cardiff Oncology's Net Income for the
three
months ended in Mar. 2026 was $-12.35 Mil. Cardiff Oncology's Revenue for the
three
months ended in Mar. 2026 was $0.04 Mil. Therefore, Cardiff Oncology's net margin for the quarter that ended in Mar. 2026 was -30,109.76%.
The historical rank and industry rank for Cardiff Oncology's Net Margin % or its related term are showing as below:
CRDF'
s Net Margin % Range Over the Past 10 Years
Min: -10289.76 Med: -7215.82 Max: -4354.76
Current: -8526.1
CRDF's Net Margin % is ranked worse than 92.71% of 947
companies
in the Biotechnology industry
Industry Median: -89.33
vs CRDF: -8526.10
Cardiff Oncology (NAS:CRDF) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Cardiff Oncology Net Margin % Related Terms
Cardiff Oncology Net Margin % Historical Data
* Premium members only.
The historical data trend for Cardiff Oncology's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Cardiff Oncology's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cardiff Oncology Net Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cardiff Oncology's Net Margin % distribution charts can be found below:
* The bar in red indicates where Cardiff Oncology's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cardiff Oncology (CRDF) has a Net Margin % of -30,109.76% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Cardiff Oncology and its competitors. According to the industry distribution chart, Cardiff Oncology ranks #878 out of 947 companies in the Biotechnology industry, placing it in the top 92.7%.
Is Cardiff Oncology's Net Margin % too high?
Cardiff Oncology's current Net Margin % is -30,109.76%. Based on the distribution chart, Cardiff Oncology ranks #878 out of 947 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Cardiff Oncology has a GF Score™ of 53/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Cardiff Oncology's Net Margin % compare to VTVT and GUTS?
According to the Biotechnology industry distribution chart, Cardiff Oncology ranks #878 out of 947 companies for Net Margin %. This places Cardiff Oncology in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Cardiff Oncology and its competitors. Cardiff Oncology's current Net Margin % is -30,109.76%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cardiff Oncology stock overvalued right now?
Based on GuruFocus' analysis, Cardiff Oncology (CRDF) is currently considered Modestly Undervalued. The stock's GF Value™ is $1.49, compared to a current price of $1.21 — trading 18.8% below its estimated fair value. The current Net Margin % is -30,109.76%. Cardiff Oncology's overall GF Score™ is 53/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Cardiff Oncology (CRDF), the current Net Margin % is -30,109.76% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cardiff Oncology (CRDF) Overvalued in 2026?
Based on GuruFocus' analysis, Cardiff Oncology stock appears to be undervalued.
The current stock price of $1.21 is trading 18.8% below its estimated GF Value™ of $1.49.
GuruFocus considers Cardiff Oncology to be Modestly Undervalued.
Key valuation signals for CRDF:
Net Margin %: -30,109.76%
GF Value™: $1.49 vs. price of $1.21 (18.8% below fair value)
No single metric tells the full story. See the CRDF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cardiff Oncology Inc is a clinical-stage biotechnology company that leverages PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies for various cancers with unmet medical needs. The company focuses on targeting tumor vulnerabilities with treatment combinations of onvansertib, its oral and selective PLK1 inhibitor, and standard-of-care (SoC) therapeutics. The firm's clinical program pipeline focuses on indications such as RAS-mutated metastatic colorectal cancer (mCRC), investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), metastatic triple negative breast cancer (mTNBC), and Chronic Myelomonocytic Leukemia (CMML). Geographically, it operates only in the United States.
53GF Score
Get the complete analysis for CRDF
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CRDF has been successfully added to your 
